Q2 EARNINGS: Covidien predicts Q3 double-digit EPS growth
This article was originally published in Clinica
Executive Summary
Covidien’s second-quarter sales grew 3% year-on-year, or 4% at constant exchange rates, to $2.60bn. The firm’s largest division, surgical solutions, was also the biggest grower, with revenues up 4% year-on-year.